Antibacterial Peptide Could Aid in Treating Soldiers’ Burn Wound Infections
ScienceDaily (Sep. 2, 2010) — An antibacterial peptide developed by Laszlo Otvos, a research professor of biology in Temple’s College of Science and Technology, looks to be a highly-effective therapy against infections in burn or blast wounds suffered by soldiers.
Otvos and his collaborators found that when given intramuscularly the peptide A3-APO was more effective than current antimicrobial chemotherapy measures in treating multidrug-resistant Acinetobacter baumannii, the most common systemic infection found in soldiers who suffer burn or blast wounds. The peptide is also highly efficacious in models of multi-drug resistant systemic Escherichia coli infections.
Their findings are being published in the Journal of Antimicrobial Chemotherapy.
Currently, these infections are treated with an antibiotic, either imipenem or colistin. However, both of these rapidly lose efficacy due to high rates of antimicrobial resistance. In addition, colistin is a strongly toxic drug and worldwide research is focusing on its replacement options.
“This is the first peptide ever that is more efficacious in an animal model than anything else that is available,” said Otvos, who hopes the peptide can be tested in clinical trials in the near future.